Quarterly ResultMay 14, 2026, 04:07 PM
Moleculin Biotech Q1 Net Loss $(12.8M); Going Concern Doubt Raised
AI Summary
Moleculin Biotech reported a net loss of $(12.8) million for Q1 2026, significantly wider than the $(5.9) million loss in Q1 2025. The company's cash on hand of $10.3 million is deemed insufficient to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern. During the quarter, the company generated $8.3 million gross proceeds from warrant inducement agreements and also implemented a 1-for-25 reverse stock split in December 2025.
Key Highlights
- Net loss widened to $(12.8) million in Q1 2026 from $(5.9) million in Q1 2025.
- Net loss per common share was $(3.54) in Q1 2026, compared to $(15.80) in Q1 2025.
- Cash and cash equivalents increased to $10.3 million as of March 31, 2026, from $8.9 million at December 31, 2025.
- Accumulated deficit reached $218.8 million as of March 31, 2026.
- Company's cash on hand ($10.3M) is insufficient to fund operations for at least one year, raising going concern doubt.
- Generated $8.3 million gross proceeds from warrant inducement agreements in February 2026.
- Research and development expenses increased to $5.4 million in Q1 2026 from $3.4 million in Q1 2025.
- Effected a 1-for-25 reverse stock split on December 1, 2025.